Key Points
- Insider sale: Director David Myles sold 50,000 shares on January 13 at an average price of $27.60 for $1.38M, trimming his stake by 8.44% to 542,761 shares (≈$14.98M).
- Analyst sentiment: The stock carries a consensus "Moderate Buy" rating with a $41 average target and several firms (Oppenheimer, UBS, Piper Sandler, HC Wainwright) issuing buy/overweight ratings and raising targets into the $40–$48 range.
- Institutional backing and company profile: Institutions own 91.78% of the shares with recent increases from firms like Hennion & Walsh and Paradigm Biocapital, while Olema is a clinical‑stage biopharma (lead candidate OP‑1250 in Phase 3) trading with negative EPS and a market cap of about $1.98B.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) insider David Myles sold 10,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $28.34, for a total value of $283,400.00. Following the transaction, the insider directly owned 144,846 shares in the company, valued at approximately $4,104,935.64. This trade represents a 6.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Olema Pharmaceuticals Price Performance
OLMA stock opened at $28.77 on Thursday. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $1.98 billion, a P/E ratio of -15.38 and a beta of 1.92. The business has a 50 day simple moving average of $24.28 and a 200-day simple moving average of $13.00. Olema Pharmaceuticals, Inc. has a twelve month low of $2.86 and a twelve month high of $36.26.
Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05). As a group, equities analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. lifted its holdings in Olema Pharmaceuticals by 55.4% in the second quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company's stock valued at $26,000 after acquiring an additional 2,168 shares during the period. ProShare Advisors LLC increased its holdings in shares of Olema Pharmaceuticals by 21.1% in the 2nd quarter. ProShare Advisors LLC now owns 14,766 shares of the company's stock valued at $63,000 after purchasing an additional 2,569 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Olema Pharmaceuticals by 0.4% in the third quarter. Bank of America Corp DE now owns 802,304 shares of the company's stock valued at $7,855,000 after purchasing an additional 2,802 shares during the period. FNY Investment Advisers LLC boosted its holdings in Olema Pharmaceuticals by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company's stock worth $42,000 after buying an additional 5,000 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in Olema Pharmaceuticals during the third quarter worth about $53,000. Hedge funds and other institutional investors own 91.78% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on OLMA. Citigroup boosted their price target on Olema Pharmaceuticals from $21.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, December 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Olema Pharmaceuticals in a report on Wednesday, October 8th. Oppenheimer increased their price target on Olema Pharmaceuticals from $45.00 to $48.00 and gave the stock an "outperform" rating in a report on Thursday, December 11th. Piper Sandler initiated coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, January 7th. They issued an "overweight" rating and a $40.00 price objective on the stock. Finally, The Goldman Sachs Group raised their target price on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a "buy" rating in a research note on Thursday, December 11th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Olema Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $41.00.
Get Our Latest Report on Olema Pharmaceuticals
About Olema Pharmaceuticals
(
Get Free Report)
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
